Research
Hormonal
Semaglutide 2.4 mg once weekly is the preferred first-line anti-obesity medication for individuals with obesity and chronic kidney disease (CKD), including non-diabetic populations, due to significant reductions in renal endpoint progression.
If you have obesity and chronic kidney disease, semaglutide 2.4 mg once weekly is the preferred first-line treatment to significantly slow kidney function decline and reduce the risk of needing dialysis or kidney replacement therapy, even if you do not have diabetes.
StrongSupportsVERY_HIGH confidence
Semaglutide should be preferred as first-line AOM in people with obesity and CKD, including non-diabetic populations, based on renal and CV outcome data. In the SELECT trial, semaglutide 2.4 mg reduced a composite renal endpoint (≥ 50% eGFR decline, macroalbuminuria onset, or need for renal replacement therapy) by 22% vs. placebo [17].
Why this rating
Based on a large, phase III randomized controlled trial (SELECT) with prespecified renal endpoints.
Source
Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan
Dario Tuccinardi et al. · Journal of Endocrinological Investigation · 2025
narrative_reviewCited 9×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →